The role of the microbiota in the antipsychotic-related weight gain

Journal title PNEI REVIEW
Author/s Francesca Bertossi
Publishing Year 2022 Issue 2022/2
Language Italian Pages 15 P. 108-122 File size 117 KB
DOI 10.3280/PNEI2022-002010
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

The treatment of a sever metal disorder and the relapse prevention implies long term antipsychotic therapy. Although second generation antipsychotics have less extrapyramidal effects, they are burden by metabolic side effects and by the weight gain risk, mediated by both their action on central and peripheral receptors and the modification on gut microbiota. There are several evidences about the role of gut microbiota in inducing wei- ght gain and metabolic alterations by second generation antipsychotics. This can happen through and altered satiety signaling, the reduction of energy expenditure, altered lipid and glucose metabolism, inflammatory modifica tions and altered intestinal barrier permeability. In the prevention and treatment of antipsychotic associate weight gain the modulation of gut microbiota and dysbiosis treatment can also be effective in and integrated approach that considers weight gain drug treatment, nutritional and physical activity programs. Among the different probiotic treatments available, Akkermansia muchini- phila seems to be the most effective in reducing weigh gain and metabolic dysfunction.

Keywords: Second generation antipsychotics, Microbiota, Obesity, SCFA, Akker- mansia muciniphila, Probiotics.

  1. Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Re- ali L., Anania F., & Nobili V. (2014). Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmaco- logy & Therapeutics, 39(11), 1276–1285.
  2. Bahr S.M., Weidemann B.J., Castro A.N., Walsh J.W., deLeon O., Burnett C.M.L., Pearson N.A., Murry D.J., Grobe J.L., & Kirby J.R. (2015). Risperidone-indu- ced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine, 2(11), 1725–1734.
  3. Clarke G., Sandhu K.V., Griffin B.T., Dinan T.G., Cryan J.F., & Hyland N.P. (2019). Gut Reactions: Breaking Down Xenobiotic–Microbiome Inte- ractions. Pharmacological Reviews, 71(2), 198–224.
  4. Cryan J.F., O’Riordan K.J., Cowan C.S.M., Sandhu K.V., Bastiaanssen T.F.S., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., Guzzetta K.E., Jaggar M., Long-Smith C.M., Lyte J.M., Martin J.A., Moline- ro-Perez A., Moloney G., Morelli E., Morillas E., O’Connor R., Cruz-Perei- ra J.S., Peterson V.L., Rea K., Ritz N.L., Sherwin E., Spichak S., Teichman E.M., van de Wouw M., Ventura-Silva A.P., Wallace-Fitzsimons S.E., Hyland N., Clarke G., & Dinan T.G. (2019). The Microbiota-Gut-Brain Axis. Physio- logical Reviews, 99(4), 1877–2013.
  5. Cussotto S., Clarke G., Dinan T.G., & Cryan J.F. (2019). Psychotropics and the Microbiome: a Chamber of Secrets…. Psychopharmacology, 236(5), 1411– 1432.
  6. Dao M.C., Everard A., Aron-Wisnewsky J., Sokolovska N., Prifti E., Verger E.O., Kayser B.D., Levenez F., Chilloux J., Hoyles L., MICRO-Obes Consor- tium, Dumas M.-E., Rizkalla S.W., Doré J., Cani P.D., & Clément K. (2016). Akkermansia muciniphila and improved metabolic health during a dietary inter- vention in obesity: relationship with gut microbiome richness and ecology. Gut, 65(3), 426–436.
  7. Davey K.J., Cotter P.D., O’Sullivan O., Crispie F., Dinan T.G., Cryan J.F., & O’Mahony S.M. (2013). Antipsychotics and the gut microbiome: olanzapine-in- duced metabolic dysfunction is attenuated by antibiotic administration in the rat. Translational Psychiatry, 3(10), e309–e309.
  8. De Meyts P., & Delzenne N. (2021). Editorial: The Brain – Gut – Microbiome Network in Metabolic Regulation and Dysregulation. Frontiers in Endocrinolo- gy, 12, 760558.
  9. Depommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N.M., de Barsy M., Loumaye A., Hermans M.P., Thissen J.-P., de Vos W.M., & Cani P.D. (2019). Supplementa- tion with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine, 25(7), 1096–1103.
  10. Derrien M., Vaughan E.E., Plugge C.M., & de Vos W.M. (2004). Akkerman- sia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacte- rium. International Journal of Systematic and Evolutionary Microbiology, 54(5), 1469–1476.
  11. Ejtahed H.-S., Angoorani P., Soroush A.-R., Atlasi R., Hasani-Ranjbar S., Mortazavian A.M., & Larijani B. (2019). Probiotics supplementation for the obesity management; A systematic review of animal studies and clinical trials. Journal of Functional Foods, 52, 228–242.
  12. Flowers S.A., Evans S.J., Ward K.M., McInnis M.G., & Ellingrod V.L. (2017). Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37(3), 261–267.
  13. Green M., Arora K., & Prakash S. (2020). Microbial Medicine: Prebiotic and Pro- biotic Functional Foods to Target Obesity and Metabolic Syndrome. International Journal of Molecular Sciences, 21(8), 2890.
  14. Huang D., Gao J., Li C., Nong C., Huang W., Zheng X., Li S., & Peng Y. (2021). A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mecha- nisms underpinning how Akkermansia muciniphila subtype improves olanzapine-in- duced glucose homeostasis in mice. Psychopharmacology, 238(9), 2543–2553.
  15. Marteene W., Winckel K., Hollingworth S., Kisely S., Gallagher E., Hahn M., Ebdrup B.H., Firth J., & Siskind D. (2019). Strategies to counter antipsychotic-as- sociated weight gain in patients with schizophrenia. Expert Opinion on Drug Safety, 18(12), 1149–1160. DOI: 10.1080/14740338.2019.167480
  16. Martin-Gallausiaux C., Marinelli L., Blottière H.M., Larraufie P., & Lapaque N. (2021). SCFA: mechanisms and functional importance in the gut. Proceedings of the Nutrition Society, 80(1), 37–49. DOI: 10.1017/S002966512000691
  17. Plovier H., Everard A., Druart C., Depommier C., Van Hul M., Geurts L., Chil- loux J., Ottman N., Duparc T., Lichtenstein L., Myridakis A., Delzenne N.M., Klievink J., Bhattacharjee A., van der Ark K.C.H., Aalvink S., Martinez L.O., Dumas M.-E., Maiter D., Loumaye A., Hermans M.P., Thissen J.-P., Belzer C., de Vos W.M., & Cani P.D. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine, 23(1), 107–113.
  18. Portincasa P., Bonfrate L., Khalil M., Angelis M.D., Calabrese F.M., D’Ama- to M., Wang D.Q.-H., & Di Ciaula A. (2021). Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines, 10(1), 83.
  19. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., & Gordon
  20. J.I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031.
  21. van de Wouw M., Schellekens H., Dinan T.G., & Cryan J.F. (2017). Microbio- ta-Gut-Brain Axis: Modulator of Host Metabolism and Appetite. The Journal of Nutri- tion, 147(5), 727–745.
  22. Zhang T., Li Q., Cheng L., Buch H., & Zhang F. (2019). Akkermansia muciniphi- la is a promising probiotic. Microbial Biotechnology, 12(6), 1109–1125. DOI: 10.1111/1751-7915.1341
  23. Zhou K. (2017). Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. Journal of Functional Foods, 33, 194–201.

Francesca Bertossi, Il ruolo del microbiota nell’aumento ponderale associato alla terapia antipsicotica in "PNEI REVIEW" 2/2022, pp 108-122, DOI: 10.3280/PNEI2022-002010